BofA analyst Alec Stranahan lowered the firm’s price target on NextCure to $1 from $5 and keeps an Underperform rating on the shares. The firm’s bearish thesis is inflated by the discontinuation of NC318, lack of actionable data from SITC, and the difficult setup for NC410 given the lack of clinical validation of FIND-10, Stranahan tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NXTC:
- NextCure to Present at Upcoming Investor Conferences
- NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
- NextCure presents initial data from trial of NC762, progress for NC410 combo
- NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
- NextCure Provides Update and Reports Third Quarter 2022 Financial Results
